机构地区：[1]Department of Psychiatry,National Clinical Research Center for Mental Disorders,National Center for Mental Disorders,The Second Xiangya Hospital of Central South University,Changsha 410011,Hunan Province,China [2]Department of Psychiatry,Hebei Provincial Mental Health Center,Hebei Key Laboratory of Major Mental and Behavioral Disorders,The Sixth Clinical Medical College of Hebei University,Baoding 071000,Hebei Province,China [3]Department of Psychiatry,Brain Hospital of Hunan Province,Changsha 410000,Hunan Province,China [4]Department of Psychiatry,The First Psychiatric Hospital of Harbin,Harbin 150000,Heilongjiang Province,China [5]Mental Health Center,Changchun Sixth Hospital,Changchun 130000,Jilin Province,China [6]Department of Pharmacy,Daqing Third Hospital,Daqing 163000,Heilongjiang Province,China [7]Department of Physical and Psychological Rehabilitation,Guangda Rehabilitation Hospital,Chongqing 400000,China [8]Department of Psychology,Shanxi Provincial Mental Health Center,Taiyuan 030000,Shanxi Province,China [9]Department of Psychiatry,Tianjin Anding Hospital,Tianjin 300000,China [10]Department of Psychiatry,Shandong Mental Health Center,Jinan 250000,Shandong Province,China [11]Department of Psychiatry,Fuzhou Shenkang Hospital,Fuzhou 350000,Fujian Province,China [12]Department of Psychiatry,Shanghai Mental Health Center,Shanghai Jiao Tong University School of Medicine,Shanghai 200000,China [13]Department of Psychiatry,The Second Affiliated Hospital of Xinxiang Medical University,Xinxiang 453000,Henan Province,China [14]Department of Psychiatry,The Fifth People’s Hospital of Zigong,Zigong 643000,Sichuan Province,China [15]Department of Psychiatry,The Affiliated Kangning Hospital of Wenzhou Medical University,Wenzhou 325000,Zhejiang Province,China [16]Department of Psychiatry,Guangyuan Mental Health Center,Guangyuan 628000,Sichuan Province,China [17]Department of Psychiatry,Jilin Sixth People’s Hospital,Jilin 132000,Jilin Province,China [18]The National Clinical Research Center for Mental Disorders&
出 处：《World Journal of Psychiatry》2024年第11期1735-1745,共11页世界精神病学杂志（英文）
摘 要：BACKGROUND Blonanserin(BNS)is a well-tolerated and effective drug for treating schizophrenia.AIM To investigate which types of patients would obtain the most benefit from BNS treatment.METHODS A total of 3306 participants were evaluated in a 12-week,prospective,multicenter,open-label post-marketing surveillance study of BNS.Brief psychiatric rating scale(BPRS)scores were calculated to evaluate the effectiveness of BNS,and its safety was assessed with the incidence of adverse drug reactions.Linear regression was used to screen the influencing factors for the reduction of BPRS total score,and logistic regression was used to identify patients with a better response to BNS.RESULTS The baseline BPRS total score(48.8±15.03)decreased to 27.7±10.08 at 12 weeks(P<0.001).Extrapyramidal symptoms(14.6%)were found to be the most frequent adverse drug reactions.The acute phase,baseline BPRS total score,current episode duration,number of previous episodes,dose of concomitant antipsychotics,and number of types of sedative-hypnotic agents were found to be independent factors affecting the reduction of BPRS total score after treatment initiation.Specifically,patients in the acute phase with baseline BPRS total score≥45,current episode duration<3 months,and≤3 previous episodes derived greater benefit from 12-week treatment with BNS.CONCLUSION Patients in the acute phase with more severe symptoms,shorter current episode duration,fewer previous episodes,and a lower psychotropic drug load derived the greatest benefit from treatment with BNS.
关 键 词：SCHIZOPHRENIA BLONANSERIN EFFECTIVENESS Psychosocial functioning Prospective cohort study
分 类 号：R749.3[医药卫生—神经病学与精神病学]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
